# A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia

Study · id `cardio:ct-nct07680829` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07680829](<https://clinicaltrials.gov/study/NCT07680829>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07680829

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 378 participants.

## Technical summary

Registry record NCT07680829. Randomized; quadruple masking; primary purpose treatment. Start 2026-08 (anticipated); primary completion 2030-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 378 participants (planned count; ClinicalTrials.gov record NCT07680829, source copy `cardio:ctgov-nct07680829-2026-07-06`, retrieved 2026-10-31)
- Planned start: 2026-08 (anticipated) (ClinicalTrials.gov record NCT07680829, source copy `cardio:ctgov-nct07680829-2026-07-06`, retrieved 2026-10-31)
- Primary completion: 2030-06 (anticipated) (ClinicalTrials.gov record NCT07680829, source copy `cardio:ctgov-nct07680829-2026-07-06`, retrieved 2026-10-31)
- Completion: 2030-10 (anticipated) (ClinicalTrials.gov record NCT07680829, source copy `cardio:ctgov-nct07680829-2026-07-06`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07680829, source copy `cardio:ctgov-nct07680829-2026-07-06`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07680829-2026-07-06`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia
- Condition: Severe Hypertriglyceridemia
- Intervention (Drug): DR10624 Subcutaneous Injection
- Intervention (Drug): Icosapent Ethyl Oral Capsule
- Intervention (Drug): Matching Placebo Subcutaneous Injection
- Lead sponsor: Zhejiang Doer Biologics Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: Zhejiang Doer Biologics Co., Ltd. (`cardio:org-zhejiang-doer-biologics-co-ltd`)

## Provenance

Content hash: 2c309794d06424a589cbde0e0690119c69aeea627f3acb3b4b28c8f2cc8400ab
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
